Table 5.
HR and 95% CI obtained from Cox regression comparing oTNFi with etanercept in patients with SpA
| Etanercept n/1000 pyr |
oTNFi n/1000 pyr |
Country* | Model 1† HR (95% CI) |
Model 2‡ HR (95% CI) |
Model 3§ HR (95% CI) |
Meta-analysis HR (95% CI) |
|
| Outcome | |||||||
| Any | 51/78 | 128/189 | Denmark | 0.74 (0.38 to 1.45) | 0.75 (0.38 to 1.46) | 0.95 (0.47 to 1.94) | 1.06 (0.75 to 1.50) |
| FI, ICE, NO, SE, pooled | 1.08 (0.74 to 1.57) | 1.09 (0.74 to 1.59) | 1.09 (0.73 to 1.63) | ||||
| DML | 41/79 | 99/189 | Denmark | 0.65 (0.28 to 1.53) | 0.65 (0.28 to 1.54) | 0.98 (0.37 to 2.55) | 1.01 (0.68 to 1.50) |
| FI, ICE, NO, SE, pooled | 1.01 (0.67 to 1.53) | 1.03 (0.68 to 1.55) | 1.01 (0.65 to 1.57) | ||||
| IPN | 10/79 | 29/189 | Denmark | 0.91 (0.31 to 2.65) | 0.91 (0.31 to 2.67) | 0.97 (0.33 to 2.89) | 1.28 (0.61 to 2.69) |
| FI, ICE, NO, SE, pooled | 0.87 (0.48 to 1.59) | 0.91 (0.50 to 1.65) | 1.00 (0.53 to 1.91) | ||||
| MS | 21/79 | 42/189 | Denmark | 0.38 (0.12 to 1.17) | 0.37 (0.12 to 1.14) | 0.71 (0.18 to 2.81) | 0.94 (0.53 to 1.69) |
| FI, ICE, NO, SE, pooled | 1.49 (0.55 to 4.09) | 1.52 (0.55 to 4.17) | 1.63 (0.59 to 4.49) |
The follow-up started at TNFi start and ended at first registered event date, emigration, death or end of the study period, whichever came first. Patients could be on any line of biological therapy.
All analyses were stratified by the number of previous biologic or targeted synthetic disease-modifying antirheumatic drugs (stratified Cox).
‘Any’ refers to any neuroinflammatory event (DML, IPN or MS).
*‘FI, ICE, NO, SE, pooled’ includes Finland, Iceland, Norway and Sweden: pooled data, analysis stratified by country (stratified Cox).
†Model 1: crude estimate.
‡Model 2: analyses were adjusted for age, sex and calendar year.
§Model 3: analyses were further adjusted for CRP, disease duration and concomitant methotrexate.
CRP, C reactive protein (mg/L); DML, demyelinating disease; IPN, inflammatory polyneuropathy; MS, multiple sclerosis; oTNFi, other tumour necrosis factor inhibitors (adalimumab, certolizumab pegol, infliximab, golimumab); pyr, person-years; SpA, spondyloarthritis (including psoriatic arthritis and ankylosing spondylitis); TNFi, tumour necrosis factor inhibitor.